Screener / SEC EDGAR /CIK 0001802768 /10-K filed Feb 11, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Royalty Pharma plc RPRX

Compare with peers Embed

RPRX among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+5.1%113th of 155 · median +10.5%
Net margin
-4.1%15.3%
25.7%15th of 154 · median 6.8%
Return on equity
-5.2%18.5%
6.9%81st of 144 · median 9.2%
Debt / equity (less is better)
1.160.42
0.8872nd of 108 · median 0.69

RPRX and 9 peers, year by year

The 9 Health care companies closest to RPRX in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
RPRX Royalty Pharma plc FY2025 $2.4B+5.1%-65.6%32.4%-7.9%0.92
QDEL QuidelOrtho Corp FY2025 $2.7B−1.9%-−33.7%−41.5%−3.0%−58.9%1.40
CHE Chemed Corp FY2025 $2.5B+4.1%-13.4%10.5%12.9%27.1%-
MRNA Moderna FY2025 $1.9B−39.9%-−158.1%−145.2%−106.2%−32.6%0.07
EXEL Exelixis, Inc. FY2025 $2.3B+7.0%-37.6%33.7%37.7%36.2%-
PRVA Privia Health Group, Inc. FY2025 $2.1B+22.3%-1.6%1.1%-3.1%-
MEDP Medpace Holdings, Inc. FY2025 $2.5B+20.0%-21.1%17.8%26.9%98.3%-
RDNT RadNet, Inc. FY2025 $2.0B+11.5%-3.0%−0.9%-−1.7%1.00
HIMS Hims & Hers Health, Inc. FY2025 $2.3B+59.0%73.8%4.5%5.5%2.4%23.7%-
NVST Envista Holdings Corp FY2025 $2.7B+8.3%54.7%7.9%1.7%8.5%1.5%0.47

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2018 to FY2025 · 10-K XBRL

RPRXRoyalty Pharma plc
FY2018 revenue $1.8BFY2019 revenue $1.8BFY2020 revenue $2.1BFY2021 revenue $2.3BFY2022 revenue $2.2BFY2023 revenue $2.4BFY2024 revenue $2.3BFY2025 revenue $2.4B FY2018 net margin 76.8%FY2019 net margin 129.4%FY2020 net margin 45.9%FY2021 net margin 27.1%FY2022 net margin 1.9%FY2023 net margin 48.2%FY2024 net margin 37.9%FY2025 net margin 32.4% FY2018FY2025
Revenue$2.4B Growth+5.1% Net margin32.4%
QDELQuidelOrtho Corp
FY2020 revenue $1.7BFY2021 revenue $1.7BFY2022 revenue $3.3BFY2023 revenue $3.0BFY2024 revenue $2.8BFY2025 revenue $2.7B FY2020 net margin 48.8%FY2021 net margin 41.5%FY2022 net margin 16.8%FY2023 net margin −0.3%FY2024 net margin −73.7%FY2025 net margin −41.5% FY2018FY2025
Revenue$2.7B Growth−1.9% Net margin−41.5%
CHEChemed Corp
FY2018 revenue $1.8BFY2019 revenue $1.9BFY2020 revenue $2.1BFY2021 revenue $2.1BFY2022 revenue $2.1BFY2023 revenue $2.3BFY2024 revenue $2.4BFY2025 revenue $2.5B FY2018 net margin 11.5%FY2019 net margin 11.3%FY2020 net margin 15.4%FY2021 net margin 12.6%FY2022 net margin 11.7%FY2023 net margin 12.0%FY2024 net margin 12.4%FY2025 net margin 10.5% FY2018FY2025
Revenue$2.5B Growth+4.1% Net margin10.5%
MRNAModerna
FY2018 revenue $135.1MFY2019 revenue $60.2MFY2020 revenue $803.0MFY2021 revenue $18.5BFY2022 revenue $19.3BFY2023 revenue $6.8BFY2024 revenue $3.2BFY2025 revenue $1.9B FY2018 net margin −284.8%FY2019 net margin −853.7%FY2020 net margin −93.0%FY2021 net margin 66.1%FY2022 net margin 43.4%FY2023 net margin −68.8%FY2024 net margin −110.0%FY2025 net margin −145.2% FY2018FY2025
Revenue$1.9B Growth−39.9% Net margin−145.2%
EXELExelixis, Inc.
FY2018 revenue $853.8MFY2019 revenue $967.8MFY2020 revenue $987.5MFY2021 revenue $1.4BFY2022 revenue $1.6BFY2023 revenue $1.8BFY2024 revenue $2.2BFY2025 revenue $2.3B FY2018 net margin 80.8%FY2019 net margin 33.2%FY2020 net margin 11.3%FY2021 net margin 16.1%FY2022 net margin 11.3%FY2023 net margin 11.4%FY2024 net margin 24.0%FY2025 net margin 33.7% FY2018FY2025
Revenue$2.3B Growth+7.0% Net margin33.7%
PRVAPrivia Health Group, Inc.
FY2019 revenue $786.4MFY2020 revenue $817.1MFY2021 revenue $966.2MFY2022 revenue $1.4BFY2023 revenue $1.7BFY2024 revenue $1.7BFY2025 revenue $2.1B FY2019 net margin 1.0%FY2020 net margin 3.8%FY2021 net margin −19.5%FY2022 net margin −0.6%FY2023 net margin 1.4%FY2024 net margin 0.8%FY2025 net margin 1.1% FY2018FY2025
Revenue$2.1B Growth+22.3% Net margin1.1%
MEDPMedpace Holdings, Inc.
FY2018 revenue $704.6MFY2019 revenue $861.0MFY2020 revenue $925.9MFY2021 revenue $1.1BFY2022 revenue $1.5BFY2023 revenue $1.9BFY2024 revenue $2.1BFY2025 revenue $2.5B FY2018 net margin 10.4%FY2019 net margin 11.7%FY2020 net margin 15.7%FY2021 net margin 15.9%FY2022 net margin 16.8%FY2023 net margin 15.0%FY2024 net margin 19.2%FY2025 net margin 17.8% FY2018FY2025
Revenue$2.5B Growth+20.0% Net margin17.8%
RDNTRadNet, Inc.
FY2018 revenue $975.1MFY2019 revenue $1.2BFY2020 revenue $1.1BFY2021 revenue $1.3BFY2022 revenue $1.4BFY2023 revenue $1.6BFY2024 revenue $1.8BFY2025 revenue $2.0B FY2018 net margin 3.3%FY2019 net margin 1.3%FY2020 net margin −1.4%FY2021 net margin 1.9%FY2022 net margin 0.7%FY2023 net margin 0.2%FY2024 net margin 0.2%FY2025 net margin −0.9% FY2018FY2025
Revenue$2.0B Growth+11.5% Net margin−0.9%
HIMSHims & Hers Health, Inc.
FY2019 revenue $82.6MFY2020 revenue $148.8MFY2021 revenue $271.9MFY2022 revenue $526.9MFY2023 revenue $872.0MFY2024 revenue $1.5BFY2025 revenue $2.3B FY2019 net margin −87.3%FY2020 net margin −12.2%FY2021 net margin −39.6%FY2022 net margin −12.5%FY2023 net margin −2.7%FY2024 net margin 8.5%FY2025 net margin 5.5% FY2018FY2025
Revenue$2.3B Growth+59.0% Net margin5.5%
NVSTEnvista Holdings Corp
FY2018 revenue $2.8BFY2019 revenue $2.3BFY2020 revenue $1.9BFY2021 revenue $2.5BFY2022 revenue $2.6BFY2023 revenue $2.6BFY2024 revenue $2.5BFY2025 revenue $2.7B FY2018 net margin 8.1%FY2019 net margin 9.5%FY2020 net margin 1.7%FY2021 net margin 13.6%FY2022 net margin 9.5%FY2023 net margin −3.9%FY2024 net margin −44.6%FY2025 net margin 1.7% FY2018FY2025
Revenue$2.7B Growth+8.3% Net margin1.7%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2018 to FY2025

Revenue as reported in the 10-K.

50 200 1000 5000 100 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, $1.7B, $1.7B, $3.3B, $3.0B, $2.8B, $2.7B QDEL CHE: $1.8B, $1.9B, $2.1B, $2.1B, $2.1B, $2.3B, $2.4B, $2.5B CHE MRNA: $135.1M, $60.2M, $803.0M, $18.5B, $19.3B, $6.8B, $3.2B, $1.9B MRNA EXEL: $853.8M, $967.8M, $987.5M, $1.4B, $1.6B, $1.8B, $2.2B, $2.3B EXEL PRVA: -, $786.4M, $817.1M, $966.2M, $1.4B, $1.7B, $1.7B, $2.1B PRVA MEDP: $704.6M, $861.0M, $925.9M, $1.1B, $1.5B, $1.9B, $2.1B, $2.5B MEDP RDNT: $975.1M, $1.2B, $1.1B, $1.3B, $1.4B, $1.6B, $1.8B, $2.0B RDNT HIMS: -, $82.6M, $148.8M, $271.9M, $526.9M, $872.0M, $1.5B, $2.3B HIMS NVST: $2.8B, $2.3B, $1.9B, $2.5B, $2.6B, $2.6B, $2.5B, $2.7B NVST RPRX: $1.8B, $1.8B, $2.1B, $2.3B, $2.2B, $2.4B, $2.3B, $2.4B RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. Each company's first year in the window is 100, on a log scale: a line twice as high has doubled. A gap is a year with no number. A ring marks where a line starts: QDEL, PRVA, HIMS have no earlier 10-K here. NVST: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2018 to FY2025

Revenue against the fiscal year before.

−64.4% +93.8% FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, -, +2.2%, +92.3%, −8.2%, −7.2%, −1.9% QDEL CHE: +7.0%, +7.0%, +4.2%, −5.5%, −4.7%, +9.4%, +7.4%, +4.1% CHE MRNA: −34.4%, −55.4%, n/m, n/m, +4.3%, −64.4%, −52.7%, −39.9% MRNA EXEL: +88.7%, +13.3%, +2.0%, +45.3%, +12.3%, +13.6%, +18.5%, +7.0% EXEL PRVA: -, -, +3.9%, +18.3%, +40.4%, +22.2%, +4.7%, +22.3% PRVA MEDP: +61.5%, +22.2%, +7.5%, +23.4%, +27.8%, +29.2%, +11.8%, +20.0% MEDP RDNT: +5.7%, +18.4%, −7.1%, +22.7%, +8.7%, +13.0%, +13.2%, +11.5% RDNT HIMS: -, -, +80.2%, +82.8%, +93.8%, +65.5%, +69.3%, +59.0% HIMS NVST: +1.2%, −3.3%, −15.6%, +30.1%, +2.4%, −0.1%, −2.2%, +8.3% NVST RPRX: -, +1.1%, +17.0%, +7.9%, −2.3%, +5.2%, −3.9%, +5.1% RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −64.4% to +93.8%. A gap is a year with no number. A ring marks where a line starts: RPRX, QDEL, PRVA, HIMS have no earlier 10-K here.

Gross margin, FY2018 to FY2025

Gross profit / revenue.

54.0% 82.0% FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, 54.0%, 73.6%, 75.2%, 77.6%, 82.0%, 79.5%, 73.8% HIMS NVST: 56.3%, 59.1%, 54.7%, 56.9%, 57.4%, 56.1%, 54.7%, 54.7% NVST
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 54.0% to 82.0%. A gap is a year with no number. A ring marks where a line starts: HIMS has no earlier 10-K here.
CompanyFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
RPRX Dec --------
QDEL Dec --------
CHE Dec --------
MRNA Dec --------
EXEL Jan --------
PRVA Dec --------
MEDP Dec --------
RDNT Dec --------
HIMS Dec -54.0%73.6%75.2%77.6%82.0%79.5%73.8%
NVST Dec 56.3%59.1%54.7%56.9%57.4%56.1%54.7%54.7%
Peer median--------

Operating margin, FY2018 to FY2025

Operating income / revenue.

−906.8% 144.6% FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, 63.8%, 53.3%, 25.8%, 4.6%, −70.5%, −33.7% QDEL CHE: 13.7%, 13.3%, 18.7%, 16.0%, 16.1%, 15.0%, 15.1%, 13.4% CHE MRNA: −306.0%, −906.8%, −95.0%, 72.0%, 48.9%, −61.9%, −121.9%, −158.1% MRNA EXEL: 51.4%, 38.2%, 11.1%, 20.0%, 12.5%, 9.3%, 27.9%, 37.6% EXEL PRVA: -, 2.0%, 3.1%, −22.5%, −1.4%, 1.2%, 1.0%, 1.6% PRVA MEDP: 14.3%, 14.8%, 18.0%, 17.4%, 19.1%, 17.9%, 21.2%, 21.1% MEDP RDNT: 3.2%, 6.1%, 3.3%, 6.3%, 3.2%, 6.1%, 5.7%, 3.0% RDNT HIMS: -, −90.1%, −10.2%, −42.3%, −13.0%, −3.4%, 4.2%, 4.5% HIMS NVST: 10.5%, 10.3%, 2.3%, 12.2%, 12.4%, 1.2%, −41.4%, 7.9% NVST RPRX: 76.0%, 144.6%, 75.2%, 62.5%, 13.7%, 63.4%, 57.1%, 65.6% RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −906.8% to 144.6%. A gap is a year with no number. A ring marks where a line starts: QDEL, PRVA, HIMS have no earlier 10-K here.

Net margin, FY2018 to FY2025

Net income / revenue.

−853.7% 129.4% FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, 48.8%, 41.5%, 16.8%, −0.3%, −73.7%, −41.5% QDEL CHE: 11.5%, 11.3%, 15.4%, 12.6%, 11.7%, 12.0%, 12.4%, 10.5% CHE MRNA: −284.8%, −853.7%, −93.0%, 66.1%, 43.4%, −68.8%, −110.0%, −145.2% MRNA EXEL: 80.8%, 33.2%, 11.3%, 16.1%, 11.3%, 11.4%, 24.0%, 33.7% EXEL PRVA: -, 1.0%, 3.8%, −19.5%, −0.6%, 1.4%, 0.8%, 1.1% PRVA MEDP: 10.4%, 11.7%, 15.7%, 15.9%, 16.8%, 15.0%, 19.2%, 17.8% MEDP RDNT: 3.3%, 1.3%, −1.4%, 1.9%, 0.7%, 0.2%, 0.2%, −0.9% RDNT HIMS: -, −87.3%, −12.2%, −39.6%, −12.5%, −2.7%, 8.5%, 5.5% HIMS NVST: 8.1%, 9.5%, 1.7%, 13.6%, 9.5%, −3.9%, −44.6%, 1.7% NVST RPRX: 76.8%, 129.4%, 45.9%, 27.1%, 1.9%, 48.2%, 37.9%, 32.4% RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −853.7% to 129.4%. A gap is a year with no number. A ring marks where a line starts: QDEL, PRVA, HIMS have no earlier 10-K here.

Free cash flow, FY2018 to FY2025

Cash from operations minus capital spending.

−$4.1B $13.3B FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, $564.8M, $513.1M, $744.4M, $70.9M, −$112.1M, −$83.0M QDEL CHE: $234.3M, $248.2M, $430.5M, $249.9M, $252.6M, $273.4M, $368.0M, $325.5M CHE MRNA: −$436.6M, −$491.0M, $2.0B, $13.3B, $4.6B, −$3.8B, −$4.1B, −$2.1B MRNA EXEL: $382.4M, $514.1M, $178.6M, $346.6M, $334.9M, $292.9M, $671.5M, $875.8M EXEL PRVA: -, $18.6M, $38.5M, $54.5M, $47.1M, $80.7M, -, - PRVA MEDP: $140.6M, $184.0M, $227.3M, $235.1M, $351.2M, $396.7M, $572.3M, $681.9M MEDP RDNT: $44.6M, $30.2M, -, -, -, -, -, - RDNT HIMS: -, -, -, -, −$33.7M, $47.0M, $198.3M, $57.4M HIMS NVST: $327.9M, $319.7M, $236.2M, $306.9M, $107.0M, $217.5M, $302.7M, $230.4M NVST
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$4.1B to $13.3B. A gap is a year with no number. A ring marks where a line starts: QDEL, PRVA, HIMS have no earlier 10-K here.

FCF margin, FY2018 to FY2025

Free cash flow / revenue.

−815.5% 244.0% FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, 34.0%, 30.2%, 22.8%, 2.4%, −4.0%, −3.0% QDEL CHE: 13.1%, 12.8%, 20.7%, 11.7%, 11.8%, 12.1%, 15.1%, 12.9% CHE MRNA: −323.3%, −815.5%, 244.0%, 72.2%, 23.8%, −55.9%, −125.3%, −106.2% MRNA EXEL: 44.8%, 53.1%, 18.1%, 24.2%, 20.8%, 16.0%, 31.0%, 37.7% EXEL PRVA: -, 2.4%, 4.7%, 5.6%, 3.5%, 4.9%, -, - PRVA MEDP: 19.9%, 21.4%, 24.6%, 20.6%, 24.1%, 21.0%, 27.1%, 26.9% MEDP RDNT: 4.6%, 2.6%, -, -, -, -, -, - RDNT HIMS: -, -, -, -, −6.4%, 5.4%, 13.4%, 2.4% HIMS NVST: 11.5%, 14.0%, 12.2%, 12.2%, 4.2%, 8.5%, 12.1%, 8.5% NVST
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −815.5% to 244.0%. A gap is a year with no number. A ring marks where a line starts: QDEL, PRVA, HIMS have no earlier 10-K here.

Return on equity, FY2018 to FY2025

Net income / shareholders' equity at the year end.

−68.8% 98.3% FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, 60.8%, 36.5%, 11.1%, −0.2%, −68.8%, −58.9% QDEL CHE: 34.8%, 30.3%, 35.4%, 43.1%, 31.3%, 24.6%, 27.0%, 27.1% CHE MRNA: −25.1%, −43.7%, −29.2%, 86.3%, 43.7%, −34.0%, −32.7%, −32.6% MRNA EXEL: 53.6%, 19.0%, 5.9%, 10.5%, 7.3%, 9.2%, 23.2%, 36.2% EXEL PRVA: -, 7.7%, 21.3%, −44.1%, −1.7%, 4.1%, 2.3%, 3.1% PRVA MEDP: 12.2%, 13.8%, 18.0%, 19.1%, 63.5%, 50.6%, 49.0%, 98.3% MEDP RDNT: 25.4%, 9.7%, −9.0%, 10.8%, 3.2%, 0.5%, 0.3%, −1.7% RDNT HIMS: -, n/m, n/m, −32.2%, −21.1%, −6.8%, 26.4%, 23.7% HIMS NVST: 4.8%, 6.1%, 0.9%, 8.4%, 5.8%, −2.4%, −38.1%, 1.5% NVST RPRX: 30.3%, 38.2%, 9.9%, 6.0%, 0.4%, 11.3%, 8.3%, 7.9% RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −68.8% to 98.3%. A gap is a year with no number. A ring marks where a line starts: QDEL, PRVA, HIMS have no earlier 10-K here.

Debt / equity, FY2018 to FY2025

Total debt / shareholders' equity at the year end.

0.00 5.57 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, -, 0.00, 0.54, 0.48, 0.83, 1.40 QDEL CHE: 0.15, 0.12, -, 0.30, 0.12, -, -, - CHE MRNA: -, -, -, -, -, -, 0.00, 0.07 MRNA PRVA: -, -, 0.23, 0.08, 0.00, -, -, - PRVA MEDP: 0.13, 0.00, -, 0.00, 0.13, 0.00, -, - MEDP RDNT: 5.57, 4.92, 3.94, 3.30, 2.56, 1.32, 1.13, 1.00 RDNT NVST: 0.00, 0.38, 0.72, 0.43, 0.45, 0.39, 0.51, 0.47 NVST RPRX: -, 1.02, 0.59, 0.69, 0.75, 0.61, 0.74, 0.92 RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 5.57. A gap is a year with no number. A ring marks where a line starts: RPRX, QDEL, MRNA, PRVA have no earlier 10-K here.
CompanyFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
RPRX Dec -1.020.590.690.750.610.740.92
QDEL Dec ---0.000.540.480.831.40
CHE Dec 0.150.12-0.300.12---
MRNA Dec ------0.000.07
EXEL Jan --------
PRVA Dec --0.230.080.00---
MEDP Dec 0.130.00-0.000.130.00--
RDNT Dec 5.574.923.943.302.561.321.131.00
HIMS Dec -n/mn/m-----
NVST Dec 0.000.380.720.430.450.390.510.47
Peer median0.140.250.720.190.290.440.670.73

EPS (diluted), FY2018 to FY2025

Diluted earnings per share, on today's share count after splits.

−$30.54 $28.29 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 QDEL: -, -, $18.60, $16.43, $9.56, −$0.15, −$30.54, −$16.69 QDEL CHE: $12.23, $13.31, $19.48, $16.85, $16.53, $17.93, $19.89, $18.34 CHE MRNA: −$4.95, −$1.55, −$1.96, $28.29, $20.12, −$12.33, −$9.28, −$7.26 MRNA EXEL: $2.21, $1.02, $0.35, $0.72, $0.56, $0.65, $1.76, $2.78 EXEL PRVA: -, $0.09, $0.33, −$1.83, −$0.08, $0.19, $0.11, $0.18 PRVA MEDP: $1.97, $2.67, $3.84, $4.81, $7.28, $8.88, $12.63, $15.28 MEDP RDNT: $0.66, $0.29, −$0.29, $0.46, $0.17, $0.05, $0.04, −$0.25 RDNT HIMS: -, −$2.07, −$0.51, −$0.58, −$0.32, −$0.11, $0.53, $0.51 HIMS NVST: $1.80, $1.60, $0.20, $1.92, $1.37, −$0.60, −$6.50, $0.28 NVST RPRX: -, -, $1.32, $1.49, $0.10, $2.53, $1.91, $1.78 RPRX
RPRX is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$30.54 to $28.29. A gap is a year with no number. A ring marks where a line starts: RPRX, QDEL, PRVA, HIMS have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out RPRX and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: RPRX's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.